Mucormycosis management made handy in covid era: New scoring System for Orbital Exenteration

Written By :  Dr Ishan Kataria
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-05-24 03:30 GMT   |   Update On 2021-05-24 03:59 GMT

Humans are exposed to Mucormycosis fungi on a routine basis but rarely suffered any disease as their virulence was very low. It mainly affects those who are immunocompromised with Diabetes Mellitus being the most common pre-disposing factor. The other pre-disposing diseases that may contribute to mucormycosis are prior steroid therapy.

However in covid era, this deadly fungus has caused an epidemic due to immunocompromising ability of covid 19 along with injudicious use of steroids for covid treatment.

The most common mode of spread of these fungi is through inhalation of fungal spores or conidia.Once these spores enter the tissues, they find their way into the blood vessels and get lodged there. This then induces an inflammatory reaction which leads to formation of a thrombus which enlarges in size and ultimately leads to compromised blood supply of the tissues and thence causes ischaemic necrosis. The necrosis is responsible for the blackening of the tissues which is characteristic of Mucormycosis.

Depending upon the site of entry of infection into the orbit and the structure involved, the first symptoms the patients experience are decreased vision and mono-muscular palsy leading to diplopia. Late features include complete blindness, chemosis/proptosis, total ophthalmoplegia and optic atrophy on ophthalmoscopy. Further spread intra-cranially may lead to headache, altered consciousness and death

Mucormycosis is rapidly progressive, angio-invasive, commonly fatal, opportunistic fungal infection. The most critical decision in the management of rhino-orbital mucormycosis is whether the orbit should be exenterated.The decision for exenteration often depends on the judgment of the treating otolaryngologist and the ophthalmologist.

This prompted Kshitij Shah and team to devise a scoring system which efficiently tracks the orbital involvement by the disease and also lay down the indications of orbital exenteration in rhino-orbito-cerebral mucormycosis published in Indian Journal of Otolaryngology and Head and Neck Surgery.

Aims of the study included

  1. To layout the indications of orbital exenteration in patients with rhino-orbito-cerebral mucormycosis.
  2. To devise a scoring system that predicts the stage at which the exenteration needs to be carried out.

A scoring system was devised by a team of experienced Otorhinolaryngologists and Ophthalmologists from prior experience in managing mucormycosis.

A total of 15 patients were included.

The scoring system was based on 3 main criteria, namely:

(1) clinical signs and symptoms.

(2) Direct and Indirect Ophthalmoscopy.

(3) Imaging

The scoring system was applied on the patients. Depending on the score, surgical debridement from the nasal/paranasal/oral region ± orbital exenteration was carried out within a period of 24–36 h of admission. Inj Amphotericin-B intravenously was started after an initial sensitivity test dose at strength of 1 mg/ kg/day and continued till a total dose of 2–3 g was completed.

A repeat nasal endoscopy was performed and tissue from the suspected diseased area was sent for microscopic examination on KOH mount. If KOH mount was found negative, Amphotericin-B was stopped. Patients were then discharged and followed up on OPD basis.

Based on the vision, salvage ability of the eye, likelihood of further spread and cosmesis, different number of points were given to different findings which are listed below

How the score was given:

1 point = Mild symptoms/signs

2 points = Moderate symptoms/signs

3 points = Severe symptoms/signs

A. Clinical

B. Opthalmology

C. Imaging

Based on the scoring system, it was observed that those patients who crossed a score of 23 were eligible candidates for orbital exenteration as agreed upon by the Otorhinolaryngologist and Ophthalmologists. It was found that most of these patients were in turn positive for mucormycoses on histopathology and are stable now after completion of Amphotericin therapy.

Table 1 Clinical symptoms

0

2

3

Vision

Normal or same as prior to other symptoms

Decreased vision after developing other symptoms

Total blindness

Pupil

Normal

RAPD

Fixed

Ocular motility

Normal

Extra-ocular muscle palsy/Diplopia

Fixed eyeball

Proptosis

Absent

-

Present

Intracranial spread

Normal

Headache, projectile vomiting, confusion

Altered consciousness, Pulsatile Exophthalmos, coma

Table 2 Ophthalmology

Fundus changes                                                               Points

Normal                                                                                   0

Cotton wool spots                                                                  1

Congested tortuous retinal blood vessels                              2

Optic disc oedema                                                                 2

Central retinal vein occlusion                                                 2

Central retinal artery occlusion                                              2

Retinal detachment                                                                2

Choroidal folds                                                                       2

Optic disc pallor                                                                      2

Total                                                                                      15

Table 3 Imaging

Orbital involvement by the disease

(globe/muscles/fat)                                                                 3

Intracranial spread/superior orbital fissure/

inferior orbital fissure involvement                                         3

Optic neuritis                                                                         3

Sphenoid sinus involvement                                                 2

Frontal sinus involvement                                                     1

Ethmoidal sinus involvement                                                1

Infra-temporal fossa involvement                                         1

Maxillary sinus involvement                                                 1

Management

  • Surgical debridement of all the necrosed tissue along with Inj Amphotericin-B (1 mg/ kg/day for a total dose of 2–3 g) is the treatment of choice.

However, when the orbit is involved the decision making is not as direct. The vision is arguably the most important sensation of a human being. The decision to either preserve the eye or exenterate it as a part of surgical debridement has to be taken jointly by the otolaryngologists and the ophthalmologists.

  • Orbital Exenteration with Enucleation
  • Endoscopic Orbital Exenteration
  • Amphotericin-B
  • Orbital Reconstruction

The above comprise preferred management options for mucormycosis treatment. The decision has to be a close balance between preserving the eye or preventing further intra-cranial spread and eventually death.

New Management options include

  • Posaconazole : It was given after 6 weeks of unresponsive Amphotericin-B treatment and there was significant clinical improvement as early as 7 days into the treatment with continued improvement for 23 weeks of therapy and no adverse reactions attributable to Posaconazole.
  • HBO2 and G-CSF are the other medical management options that have shown some promise. They act by enhancing the leukocyte killing capacity and increase oxygen delivery to the tissues. Their role is however only additive to systemic anti-fungals.

The Sion Hospital Scoring System is an accurate and promising measure to solve the dilemma that is associated with orbital exenteration in orbito-rhino-cerebral mucormycosis. This scoring system devised by a team of experienced Otorhinolaryngologists and Ophthalmologists from prior experience in managing mucormycosis is now extensively being used to decide the line of management for the new encounter with epidemic of the disease in the covid era.

Source: Kshitij Shah, Varun Dave, Renuka Bradoo, Chhaya Shinde, M. Prathibha; Indian J Otolaryngol Head Neck Surg

https://doi.org/10.1007/s12070-018-1293-8


Tags:    
Article Source : Indian Journal of Otolaryngology and Head and Neck Surgery

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News